Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Type of neuromuscular complications
研究概览
简要总结
MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors.
With the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis.
Yet, so far, these complications have only been documented in a few single case reports.
Our aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with neuromuscular complications of MEK inhibitors used alone or in combination
- •Age > 18 years
排除标准
- •Refusal of data collection
研究组 & 干预措施
未命名试验
干预措施: No Interventions (Other)
结局指标
主要结局
Type of neuromuscular complications
时间窗: up to 8 years
次要结局
- Time to onset after introduction of MEK inhibitors(up to 8 years)
- Severity of neuromuscular complications(up to 8 years)
- Progression with or without treatment(up to 8 years)
- Reintroduction of MEK inhibitors(up to 8 years)
研究者
Pauline DUCATEL
Doctor
Central Hospital, Nancy, France